Cerebral White Matter Injury in a Newborn Infant With COVID-19

A Case Report

Lucas Alves, MD, MSc, PhD, Thais Alcântara, MD, Adriano Hazin, MD, MSc, Leandro Lucato, MD, MSc, PhD, Jurandy Júnior Ferraz de Magalhães, MBioMed, MSc, Joao Alves, MD, MSc, PhD, and Jucille Meneses, MD, MSc, PhD

Neurology: Clinical Practice June 2022 vol. 12 no. 3 e22-e24 doi:10.1212/CPJ.0000000000001173

Abstract

Because the COVID-19 pandemic evolves, reports of neurologic manifestations and neuroimaging associated with SARS-CoV-2 have been reported in children and in neonates, although very few when compared with adults.

Objectives

To describe a 3-day-old neonate presenting afebrile seizures with a persistent positive nasopharyngeal swab for SARS-CoV-2 and neuroimaging demonstrating extensive cerebral white matter injury.

Methods

Consent was obtained to report this case. SARS-CoV-2 was tested using real-time reverse transcriptase-polymerase chain reaction amplification of virus acid from a nasopharyngeal swab. MRI of the brain was performed using axial T1, T2, fluid-attenuated inversion recovery, diffusion-weighted imaging, and T1 postcontrast sequences.

Results

Brain MRI showed restricted diffusion in the periventricular white matter, subcortical white matter, and splenium of the corpus callosum.

Discussion

Neurologic presentation of SARS-CoV-2 in newborns seems to be rare and is not fully known. SARS-CoV-2 infection should be considered in newborns with seizures and white matter abnormalities.

Case Presentation

A 3-day-old boy was born at 36.5 weeks’ gestation by vaginal delivery without complications. He presented with seizures characterized by clonic movements of the upper limbs and persistent bradypnea. Vital signs, temperature, heart rate, and blood pressure were normal. Phenobarbital was administered and repeated for persistence of seizures. Antibiotic therapy was initiated empirically, and orotracheal intubation was performed because of the recurrent apnea associated with epileptic seizures. His mother had fever and cough for 3 days before admission and tested positive in a nasopharyngeal swab for SARS-CoV-2 using real-time reverse transcriptase-PCR (rRT-PCR). CSF presented a normal cell count and protein and glucose levels. Serology for herpes virus, cytomegalovirus in the CSF, and blood and urine cultures were negative; therefore, the antibiotic treatment was stopped. The cranial CT
(64-section scanner, Brilliance CT Philips Medical Systems, The Netherlands) showed periventricular hypodensity, involving white matter and corpus callosum. A nasopharyngeal swab was performed and tested for SARS-CoV-2 using rRT-PCR and returned positive on the 2nd, 6th, 9th, and 12th days of life.

A cranial magnetic resonance imaging (1.5T system, Intera 1.5T Philips Medical Systems, The Netherlands) was performed on the 20th day of life, which revealed symmetrical restricted diffusion in the periventricular white matter, subcortical white matter, and corpus callosum (Figure). Metabolical screening for inborn errors of metabolism (chromatography of amino acids, organic acids urine, and acylcarnitine profile), SARS-CoV-2 antibodies IgG and IgM, and SARS-CoV-2 in CSF were negative. On the 16th day of life, a nasopharyngeal swab for SARS-CoV-2 PCR was negative. Throughout his hospital stay, he did not present more seizures or any respiratory symptoms. The patient was discharged on the 22nd day of life alert, breastfeeding, and without any neurologic deficit. He was seen in a medical consultation again at 2 and 6 months of age and had normal neurologic development.

Discussion

Since the first reports of respiratory symptoms caused by SARS-CoV-2 in December 2019, a growing number of case series have reported COVID-19-associated neurologic manifestations mostly in adults. Some studies in adults found mainly the following abnormalities: meningitis, acute disseminated encephalomyelitis, and venous thrombosis.

There are very few reports of important neurologic complications of SARS-CoV-2 in children, especially in neonates. It remains unclear whether the neurologic symptoms and neuroimaging abnormalities due to SARS-CoV-2 are caused by neuroinvasion of the virus, thromboembolic or immune-mediated phenomenon associated with the virus. We believe that in this case it was probably the latter, an intense inflammatory response against the virus due to cytokine release, resulting in diffuse brain dysfunction.

This is the second case documenting symmetric and diffuse restricted diffusion involving the cerebral white matter and corpus callosum associated with SARS-CoV-2 in a newborn infant with afebrile seizure, similar to a case describing a 9-day-old newborn with seizures and showing the same neuroimaging as this case.

The newborn was initially in good clinical conditions and did not have a history of any antenatal complications. We were able to discard many other more frequent causes of neonatal seizures, such as acute brain injury, systemic infections, and metabolic causes. Given the persistent positive rRT-PCR for SARS-CoV-2 with the clinical presentation of seizures along with the neuroimaging, we believe that this infant presented acute encephalitis with white matter injury secondary to SARS-CoV-2 infection, probably because of postnatal transmission from his SARS-CoV-2-positive mother.

We describe a newborn with SARS-CoV-2 infection with a severe neurologic presentation and neuroimaging of an extensive symmetrical restricted diffusion in the periventricular white matter. Neurologic presentation of SARS-CoV-2 in...
newborns seems to be rare and is not fully known. SARS-CoV-2 infection should be considered in newborns with seizures and white matter abnormalities. In times of the COVID-19 pandemic, SARS-CoV-2 infection of the CNS should be part of the differential diagnosis of newborns with seizures for no apparent reason. In these cases, white matter abnormalities should be investigated through neuroimaging tests.

**Study Funding**
The authors report no targeted funding.

**Disclosure**
The authors report no disclosures relevant to the manuscript. Full disclosure form information provided by the authors is available with the full text of this article at Neurology.org/cp.

**Publication History**
Received by Neurology: Clinical Practice August 20, 2021. Accepted in final form January 12, 2022. Submitted and externally peer reviewed. The handling editor was Luca Bartolini, MD.

### References

Cerebral White Matter Injury in a Newborn Infant With COVID-19: A Case Report
Lucas Alves, Thaís Alcântara, Adriano Hazin, et al.
Neurol Clin Pract 2022;12:e22-e24 Published Online before print April 21, 2022
DOI 10.1212/CPJ.0000000000001173

This information is current as of April 21, 2022

Updated Information & Services
including high resolution figures, can be found at:
http://cp.neurology.org/content/12/3/e22.full.html

References
This article cites 7 articles, 1 of which you can access for free at:
http://cp.neurology.org/content/12/3/e22.full.html#ref-list-1

Subspecialty Collections
This article, along with others on similar topics, appears in the following collection(s):
COVID-19
http://cp.neurology.org/cgi/collection/covid_19
MRI
http://cp.neurology.org/cgi/collection/mri
Neonatal
http://cp.neurology.org/cgi/collection/neoatal

Permissions & Licensing
Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at:
http://cp.neurology.org/misc/about.xhtml#permissions

Reprints
Information about ordering reprints can be found online:
http://cp.neurology.org/misc/addir.xhtml#reprintsus

Neurol Clin Pract is an official journal of the American Academy of Neurology. Published continuously since 2011, it is now a bimonthly with 6 issues per year. Copyright © 2022 American Academy of Neurology. All rights reserved. Print ISSN: 2163-0402. Online ISSN: 2163-0933.